Achema middle east

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2016

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Smart Laboratories and the Rise of Connected Pharma Equipment Ecosystems

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.
- Advertisement -

Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2016 of $0.80 per share on the company’s common stock. The dividend is payable on September 6, 2016 to shareholders of record at the close of business on August 23, 2016. The ex-dividend date is August 19, 2016. 

 

About Johnson & Johnson 
Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. 

Press Contacts:

Ernie Knewitz 

(732) 524-6623 

(917) 697-2318 (M) 

 

Amy Jo Meyer

732-524-6678

908-616-6250 (M) 

 

Investor Contacts:

Louise Mehrotra

(732) 524-6491

 

Lesley Fishman 

(732) 524-3922

 

Latest stories

Related stories

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Smart Laboratories and the Rise of Connected Pharma Equipment Ecosystems

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

India Outpaces Global Average With 2026 Medical Trend at 11.5 Percent: Aon Reports

Cardiovascular diseases, gastrointestinal conditions and cancer are top medical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »